ReviewMissouri medicine
Medical Fraud, Mislabeling, Contamination: All Common in CBD Products.
Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.Pharmaceutical medicine · 2022Pooled it
- Development and validation of a low-cost spectrophotometric method for cannabidiol (CBD) quantification based on the Beam reaction.Journal of cannabis research · 2026Article
- Characterization of Women's Health Benefit Claims Made on Cannabis E-Commerce Platforms: A Retrospective Market Surveillance Study.American journal of preventive medicine · 2026Article
- Natural Products Derived from Cannabis sativa for Pain Management.Handbook of experimental pharmacology · 2025Review
- Research and Clinical Practice Involving the Use ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.Epilepsia open · 2024Review
- Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder.Harm reduction journal · 2024Article
- Cannabidiol in sports: insights on how CBD could improve performance and recovery.Frontiers in pharmacology · 2023Article
- Safety and risks of CBD oils purchased online: unveiling uncertain quality and vague health claims.Frontiers in pharmacology · 2023Article
- Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study.PEC innovation · 2022Article
- Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.The journal of pain · 2022Article
- Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient.Innovations in pharmacy · 2022Article
- Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33311737PMC7723146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.